{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:02:25Z","timestamp":1785250945385,"version":"3.55.0"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1 NU2RGH001919-01-00"],"award-info":[{"award-number":["1 NU2RGH001919-01-00"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006778","name":"Georgia Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006778","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128707","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T03:06:03Z","timestamp":1780023963000},"page":"128707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Global cessation of bivalent oral polio vaccine (bOPV): A comprehensive review of modeling studies from 2000 to 2025"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8120-1506","authenticated-orcid":false,"given":"Yuming","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2686-546X","authenticated-orcid":false,"given":"Pinar","family":"Keskinocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-5318","authenticated-orcid":false,"given":"Corey M.","family":"Peak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-6165","authenticated-orcid":false,"given":"Lauren N.","family":"Steimle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128707_bb0005","author":"Global Polio Eradication Initiative"},{"key":"10.1016\/j.vaccine.2026.128707_bb0010","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128707_bb0015","author":"Global Polio Eradication Initiative"},{"key":"10.1016\/j.vaccine.2026.128707_bb0020","first-page":"129","article-title":"Stopping a polio outbreak in the post-eradication era","volume":"105","author":"Fine","year":"2001","journal-title":"Dev Biol"},{"issue":"50","key":"10.1016\/j.vaccine.2026.128707_bb0025","first-page":"681","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, October 2015: conclusions and recommendations","volume":"90","author":"World Health Organization","year":"2015","journal-title":"Wkly Epidemiol Rec"},{"issue":"35","key":"10.1016\/j.vaccine.2026.128707_bb0030","doi-asserted-by":"crossref","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - Worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128707_bb0035","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/jiy739","article-title":"Inactivated poliovirus vaccine supply shortage: is there light at the end of the tunnel?","volume":"220","author":"Sutter","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128707_bb0040","author":"Molodecky"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2024.2361060","article-title":"Evolution of global polio eradication strategies: targets, vaccines, and supplemental immunization activities (SIAs)","volume":"23","author":"Thompson","year":"2024","journal-title":"Expert Rev Vaccines"},{"issue":"6738","key":"10.1016\/j.vaccine.2026.128707_bb0050","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.adu6580","article-title":"Global withdrawal of Sabin oral poliovirus type 2 vaccine in 2016","volume":"387","author":"Molodecky","year":"2025","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128707_bb0055","first-page":"261","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, April 2022: conclusions and recommendations","volume":"97","author":"World Health Organization","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.128707_bb0060","author":"World Health Organization"},{"issue":"10254","key":"10.1016\/j.vaccine.2026.128707_bb0065","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0140-6736(20)31924-3","article-title":"A history of herd immunity","volume":"396","author":"Jones","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128707_bb0070","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1086\/527402","article-title":"Vaccines for the unvaccinated: protecting the herd","volume":"197","author":"Stephens","year":"2008","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128707_bb0075","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/pathogens13060435","article-title":"Review of poliovirus transmission and economic modeling to support global polio eradication: 2020\u20132024","volume":"13","author":"Thompson","year":"2024","journal-title":"Pathogens"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128707_bb0080","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14760584.2020.1791093","article-title":"Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication","volume":"19","author":"Thompson","year":"2020","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0085","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/risa.14158","article-title":"Coordinated global cessation of oral poliovirus vaccine use: options and potential consequences","volume":"44","author":"Kalkowska","year":"2024","journal-title":"Risk Anal"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128707_bb0090","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/pathogens13090804","article-title":"Increasing population immunity prior to globally-coordinated cessation of bivalent oral poliovirus vaccine (bOPV)","volume":"13","author":"Badizadegan","year":"2024","journal-title":"Pathogens"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/erv.11.195","article-title":"Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation","volume":"11","author":"Thompson","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128707_bb0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.12688\/gatesopenres.14511.1","article-title":"Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation","volume":"7","author":"Kalkowska","year":"2023","journal-title":"Gates Open Res"},{"key":"10.1016\/j.vaccine.2026.128707_bb0105","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1093\/infdis\/jix108","article-title":"Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14760584.2014.864563","article-title":"National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication","volume":"13","author":"Thompson","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128707_bb0115","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/j.1539-6924.2006.00840.x","article-title":"Risk management in a polio-free world","volume":"26","author":"Bruce Aylward","year":"2006","journal-title":"Risk Anal"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0120","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/14760584.2023.2263096","article-title":"Oral polio vaccine stockpile modeling: insights from recent experience","volume":"22","author":"Thompson","year":"2023","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128707_bb0125","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14760584.2017.1322514","article-title":"Poliovirus vaccination during the endgame: insights from integrated modeling","volume":"16","author":"Duintjer Tebbens","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijid.2013.09.005","article-title":"A quantitative survey of the literature on poliovirus infection and immunity","volume":"18","author":"Behrend","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128707_bb0135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-101416-041749","article-title":"Breaking the last chains of poliovirus transmission: Progress and challenges in global polio eradication","volume":"5","author":"Kew","year":"2018","journal-title":"Annu Rev Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/risa.13484","article-title":"Reflections on modeling poliovirus transmission and the polio eradication endgame","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2026.128707_bb0145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/sdr.1589","article-title":"Using integrated modeling to support the global eradication of vaccine-preventable diseases","volume":"34","author":"Duintjer Tebbens","year":"2018","journal-title":"Syst Dyn Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1287\/inte.2014.0769","article-title":"Polio eradicators use integrated analytical models to make better decisions","volume":"45","author":"Thompson","year":"2015","journal-title":"Interfaces"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0155","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/sdr.419","article-title":"Using system dynamics to develop policies that matter: global management of poliomyelitis and beyond","volume":"24","author":"Thompson","year":"2008","journal-title":"Syst Dyn Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128707_bb0160","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/j.1539-6924.2006.00841.x","article-title":"Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling","volume":"26","author":"Thompson","year":"2006","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2026.128707_bb0165","series-title":"Winter simulation conference proceedings","first-page":"1094","article-title":"Quantifying the impact of vaccinating under-immunized groups in polio outbreaks: a simulation-based study","author":"Sun","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128707_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2024.100476","article-title":"Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: a case study of Nigeria","volume":"18","author":"Sun","year":"2024","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2026.128707_bb0175","series-title":"Winter simulation conference proceedings","first-page":"1184","article-title":"A compartmental simulation model to improve interventions for controlling poliovirus outbreaks","author":"Sun","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128707_bb0180","doi-asserted-by":"crossref","first-page":"A93","DOI":"10.1016\/j.vaccine.2021.09.037","article-title":"Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic","volume":"41","author":"Molodecky","year":"2023","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2026.128707_bb0185","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1073\/pnas.1323688111","article-title":"The role of older children and adults in wild poliovirus transmission","volume":"111","author":"Blake","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128707_bb0190","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/aje\/kwt203","article-title":"The potential impact of routine immunization with inactivated poliovirus vaccine on wild-type or vaccine-derived poliovirus outbreaks in a posteradication setting","volume":"178","author":"Mangal","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0195","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1473-3099(23)00688-6","article-title":"Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study","volume":"24","author":"Cooper","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0200","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiad004","article-title":"The origins and risk factors for serotype-2 vaccine-derived poliovirus emergences in Africa during 2016-2019","volume":"228","author":"Gray","year":"2023","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0205","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(21)00453-9","volume":"22","author":"Cooper","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128707_bb0210","article-title":"Surveillance optimization to detect poliovirus in the pre-eradication era: a modelling study of England and Wales","author":"O\u2019Reilly","year":"2020148157","journal-title":"Epidemiol Infect"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128707_bb0215","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1716677","article-title":"Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine","volume":"379","author":"Blake","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0220","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3201\/eid2302.161210","article-title":"Estimated effect of inactivated poliovirus vaccine campaigns, Nigeria and Pakistan, January 2014-April 2016","volume":"23","author":"Shirreff","year":"2017","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0225","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12879-017-2443-4","article-title":"An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia","volume":"17","author":"O\u2019Reilly","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128707_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002323","article-title":"Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: a spatiotemporal analysis","volume":"14","author":"Molodecky","year":"2017","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128707_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005728","article-title":"Preventing vaccine-derived poliovirus emergence during the polio endgame","volume":"12","author":"Pons-Salort","year":"2016","journal-title":"PLoS Pathog"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128707_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163065","article-title":"Spatial dynamics and high risk transmission pathways of poliovirus in Nigeria 2001-2013","volume":"11","author":"Mangal","year":"2016","journal-title":"PloS One"},{"issue":"9840","key":"10.1016\/j.vaccine.2026.128707_bb0245","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(12)60648-5","article-title":"The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-11: a retrospective analysis","volume":"380","author":"O\u2019Reilly","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128707_bb0250","article-title":"A statistical model of the international spread of wild poliovirus in Africa used to predict and prevent outbreaks","volume":"8","author":"O\u2019Reilly","year":"2011","journal-title":"PLoS Med"},{"issue":"5802","key":"10.1016\/j.vaccine.2026.128707_bb0255","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1126\/science.1130388","article-title":"New strategies for the elimination of polio from India","volume":"314","author":"Grassly","year":"2006","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128707_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002140","article-title":"Population immunity against serotype-2 poliomyelitis leading up to the global withdrawal of the oral poliovirus vaccine: spatio-temporal modelling of surveillance data","volume":"13","author":"Pons-Salort","year":"2016","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2002468","article-title":"Assessing the stability of polio eradication after the withdrawal of oral polio vaccine","volume":"16","author":"Famulare","year":"2018","journal-title":"PLoS Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0270","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12916-017-0937-y","article-title":"The risk of type 2 oral polio vaccine use in post-cessation outbreak response","volume":"15","author":"McCarthy","year":"2017","journal-title":"BMC Med"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128707_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113538","article-title":"Quantifying the impact of expanded age group campaigns for polio eradication","volume":"9","author":"Wagner","year":"2014","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128707_bb0280","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/infdis\/jiad222","article-title":"Impact of supplementary immunization activities using novel oral polio vaccine type 2 during a large outbreak of circulating vaccine-derived poliovirus in Nigeria","volume":"229","author":"Voorman","year":"2024","journal-title":"J Infect Dis"},{"issue":"Suppl 1)","key":"10.1016\/j.vaccine.2026.128707_bb0285","doi-asserted-by":"crossref","first-page":"A105","DOI":"10.1016\/j.vaccine.2021.08.064","article-title":"Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies","volume":"41","author":"Voorman","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0290","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12916-017-0941-2","article-title":"Spatial model for risk prediction and sub-national prioritization to aid poliovirus eradication in Pakistan","volume":"15","author":"Mercer","year":"2017","journal-title":"BMC Med"},{"issue":"48","key":"10.1016\/j.vaccine.2026.128707_bb0295","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1016\/j.vaccine.2016.10.017","article-title":"Measuring polio immunity to plan immunization activities","volume":"34","author":"Voorman","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0300","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12916-016-0600-z","article-title":"Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria","volume":"14","author":"Upfill-Brown","year":"2016","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0305","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1741-7015-12-92","article-title":"Predictive spatial risk model of poliovirus to aid prioritization and hasten eradication in Nigeria","volume":"12","author":"Upfill-Brown","year":"2014","journal-title":"BMC Med"},{"issue":"Suppl 1(Suppl 1)","key":"10.1016\/j.vaccine.2026.128707_bb0310","doi-asserted-by":"crossref","first-page":"A85","DOI":"10.1016\/j.vaccine.2022.03.013","article-title":"Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine","volume":"41","author":"Voorman","year":"2023","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0315","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/infdis\/jiad355","article-title":"Modeling poliovirus transmission and responses in New York state","volume":"229","author":"Thompson","year":"2024","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0320","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.vaccine.2023.12.081","article-title":"Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization","volume":"42","author":"Thompson","year":"2024","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0325","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/risa.14159","article-title":"Worst-case scenarios: modeling uncontrolled type 2 polio transmission","volume":"44","author":"Kalkowska","year":"2024","journal-title":"Risk Anal"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0330","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/14760584.2023.2299401","article-title":"Modeling undetected poliovirus circulation following the 2022 outbreak in the United States","volume":"23","author":"Kalkowska","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128707_bb0335","doi-asserted-by":"crossref","first-page":"1098419","DOI":"10.3389\/fpubh.2023.1098419","article-title":"Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation","volume":"11","author":"Thompson","year":"2023","journal-title":"Front Public Health"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2026.128707_bb0340","doi-asserted-by":"crossref","first-page":"A142","DOI":"10.1016\/j.vaccine.2022.10.060","article-title":"Outbreak response strategies with type 2-containing oral poliovirus vaccines","volume":"41","author":"Kalkowska","year":"2023","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2026.128707_bb0345","doi-asserted-by":"crossref","first-page":"A136","DOI":"10.1016\/j.vaccine.2021.04.061","article-title":"Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response","volume":"41","author":"Kalkowska","year":"2023","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0350","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/risa.13982","article-title":"Modeling undetected live type 1 wild poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan","volume":"43","author":"Kalkowska","year":"2023","journal-title":"Risk Anal"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0355","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/risa.13983","article-title":"Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan","volume":"43","author":"Kalkowska","year":"2023","journal-title":"Risk Anal"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128707_bb0360","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1080\/14760584.2022.2128108","article-title":"Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036","volume":"21","author":"Thompson","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0365","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/risa.13486","article-title":"Modeling undetected live poliovirus circulation after apparent interruption of transmission: Borno and Yobe in Northeast Nigeria","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0370","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/risa.13471","article-title":"Insights from modeling preventive supplemental immunization activities as a strategy to eliminate wild poliovirus transmission in Pakistan and Afghanistan","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0375","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/risa.13664","article-title":"Health and economic outcomes associated with polio vaccine policy options: 2019\u20132029","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0380","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/risa.13590","article-title":"Expected implications of globally coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0385","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/risa.13622","article-title":"Updated characterization of outbreak response strategies for 2019\u20132029: impacts of using a novel type 2 oral poliovirus vaccine strain","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0390","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/risa.13555","article-title":"Updated characterization of post-OPV cessation risks: lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128707_bb0395","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14760584.2019.1635463","article-title":"Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)","volume":"18","author":"Thompson","year":"2019","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0400","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/risa.13193","article-title":"Environmental surveillance system characteristics and impacts on confidence about no undetected serotype 1 wild poliovirus circulation","volume":"39","author":"Kalkowska","year":"2019","journal-title":"Risk Anal"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0405","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/risa.13214","article-title":"Modeling undetected live poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan","volume":"39","author":"Kalkowska","year":"2019","journal-title":"Risk Anal"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0410","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/risa.13194","article-title":"Evaluation of proactive and reactive strategies for polio eradication activities in Pakistan and Afghanistan","volume":"39","author":"Duintjer Tebbens","year":"2019","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2026.128707_bb0415","first-page":"107","article-title":"Another look at silent circulation of poliovirus in small populations","volume":"3","author":"Kalkowska","year":"2018","journal-title":"Infect Dis Model"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128707_bb0420","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14760584.2018.1506333","article-title":"Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine","volume":"17","author":"Duintjer Tebbens","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128707_bb0425","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/risa.12962","article-title":"Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations","volume":"38","author":"Duintjer Tebbens","year":"2018","journal-title":"Risk Anal"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023938","article-title":"Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission","volume":"9","author":"Duintjer Tebbens","year":"2018","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128707_bb0435","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/fvl-2018-0079","article-title":"Poliovirus containment risks and their management","volume":"13","author":"Duintjer Tebbens","year":"2018","journal-title":"Future Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0440","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12879-018-3074-0","article-title":"Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use","volume":"18","author":"Duintjer Tebbens","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128707_bb0445","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/infdis\/jix128","article-title":"Lessons from globally coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0450","article-title":"Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use","volume":"2","author":"Duintjer Tebbens","year":"2017","journal-title":"MDM Policy Pract"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128707_bb0455","first-page":"340","article-title":"Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation","volume":"7","author":"Tebbens","year":"2016","journal-title":"J Vaccines Vacc"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128707_bb0460","first-page":"1000339","article-title":"Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management","volume":"7","author":"Duintjer Tebbens","year":"2016","journal-title":"J Vaccines Vacc"},{"key":"10.1016\/j.vaccine.2026.128707_bb0465","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12879-016-1465-7","article-title":"Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0470","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12879-016-1536-9","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0475","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12879-016-1537-8","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128707_bb0480","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.vaccine.2015.02.013","article-title":"Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses","volume":"33","author":"Thompson","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0485","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12879-015-1113-7","article-title":"Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes","volume":"15","author":"Thompson","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0490","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12879-015-1116-4","article-title":"The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission","volume":"15","author":"Thompson","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0495","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12879-015-0791-5","article-title":"Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination","volume":"15","author":"Kalkowska","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128707_bb0500","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/infdis\/jiu674","article-title":"Modeling options to manage type 1 wild poliovirus imported into Israel in 2013","volume":"211","author":"Kalkowska","year":"2015","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0505","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12879-015-1114-6","article-title":"Managing the risk of circulating vaccine-derived poliovirus during the endgame: Oral poliovirus vaccine needs","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128707_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130123","article-title":"Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of Northwest Nigeria","volume":"10","author":"Duintjer Tebbens","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128707_bb0515","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12879-015-1112-8","article-title":"An economic analysis of poliovirus risk management policy options for 2013-2052","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2026.128707_bb0520","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/infdis\/jit845","article-title":"Modeling the dynamics of oral poliovirus vaccine cessation","volume":"210","author":"Thompson","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128707_bb0525","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1093\/infdis\/jit834","article-title":"Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of Northwest Nigeria","volume":"210","author":"Kalkowska","year":"2014","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2026.128707_bb0530","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1093\/infdis\/jit844","article-title":"Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India","volume":"210","author":"Kalkowska","year":"2014","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2026.128707_bb0535","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1093\/infdis\/jit838","article-title":"Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation","volume":"210","author":"Duintjer Tebbens","year":"2014","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0540","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2334-14-45","article-title":"The potential impact of expanding target age groups for polio immunization campaigns","volume":"14","author":"Duintjer Tebbens","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0545","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1539-6924.2012.01891.x","article-title":"Modeling population immunity to support efforts to end the transmission of live polioviruses","volume":"33","author":"Thompson","year":"2013","journal-title":"Risk Anal"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128707_bb0550","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/aje\/kwr399","article-title":"The probability of undetected wild poliovirus circulation after apparent global interruption of transmission","volume":"175","author":"Kalkowska","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128707_bb0555","first-page":"190","article-title":"The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation","volume":"10","author":"Thompson","year":"2008","journal-title":"Medscape J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0560","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1539-6924.2008.01078.x","article-title":"Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management","volume":"28","author":"Duintjer Tebbens","year":"2008","journal-title":"Risk Anal"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128707_bb0565","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1539-6924.2006.00843.x","article-title":"Evaluation of response scenarios to potential polio outbreaks using mathematical models","volume":"26","author":"Thompson","year":"2006","journal-title":"Risk Anal"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128707_bb0570","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1539-6924.2006.00827.x","article-title":"Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication","volume":"26","author":"Tebbens","year":"2006","journal-title":"Risk Anal"},{"issue":"26","key":"10.1016\/j.vaccine.2026.128707_bb0575","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1016\/j.vaccine.2010.04.001","article-title":"Optimal vaccine stockpile design for an eradicated disease: application to polio","volume":"28","author":"Tebbens","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128707_bb0580","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1539-6924.2006.00842.x","article-title":"The costs of future polio risk management policies","volume":"26","author":"Tebbens","year":"2006","journal-title":"Risk Anal"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0585","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/risa.12019","article-title":"Preeradication vaccine policy options for poliovirus infection and disease control","volume":"33","author":"Thompson","year":"2013","journal-title":"Risk Anal"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0590","first-page":"35","article-title":"Policy decision options during the first 5 years following certification of polio eradication","volume":"5","author":"Sangrujee","year":"2003","journal-title":"MedGenMed"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128707_bb0595","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-016013","article-title":"Vaccination strategies against wild poliomyelitis in polio-free settings: outbreak risk modelling study and cost-effectiveness analysis","volume":"10","author":"Auzenbergs","year":"2025","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2026.128707_bb0600","doi-asserted-by":"crossref","first-page":"A19","DOI":"10.1016\/j.vaccine.2022.08.008","article-title":"Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020","volume":"41","author":"Macklin","year":"2023","journal-title":"Vaccine"},{"issue":"6489","key":"10.1016\/j.vaccine.2026.128707_bb0605","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128707_bb0610","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11538-022-01014-6","article-title":"Effect of population partitioning on the probability of silent circulation of poliovirus","volume":"84","author":"Vallejo","year":"2022","journal-title":"Bull Math Biol"},{"key":"10.1016\/j.vaccine.2026.128707_bb0615","first-page":"239","article-title":"Evaluating the probability of silent circulation of polio in small populations using the silent circulation statistic","volume":"4","author":"Vallejo","year":"2019","journal-title":"Infect Dis Model"},{"issue":"23","key":"10.1016\/j.vaccine.2026.128707_bb0620","doi-asserted-by":"crossref","first-page":"126062","DOI":"10.1016\/j.vaccine.2024.06.029","article-title":"Estimation of the poliovirus type 2 immunity gap in South Africa","volume":"42","author":"Brown","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128707_bb0625","first-page":"136","article-title":"Corrigendum to \u201cSilent circulation of poliovirus in small populations\u201d [Infectious Disease Modeling 2 (2017) 431e440]","volume":"3","author":"Vallejo","year":"2018","journal-title":"Infect Dis Model"},{"key":"10.1016\/j.vaccine.2026.128707_bb0630","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1093\/cid\/ciy605","article-title":"Assessing the risk of vaccine-derived outbreaks after reintroduction of oral poliovirus vaccine in postcessation settings","volume":"67","author":"Fu","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0635","first-page":"431","article-title":"Silent circulation of poliovirus in small populations","volume":"2","author":"Vallejo","year":"2017","journal-title":"Infect Dis Model"},{"key":"10.1016\/j.vaccine.2026.128707_bb0640","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.epidem.2017.02.013","article-title":"Dynamics affecting the risk of silent circulation when oral polio vaccination is stopped","volume":"20","author":"Koopman","year":"2017","journal-title":"Epidemics"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0645","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1186\/s12889-017-4909-0","article-title":"Assessing the impact of the Lebanese National Polio Immunization Campaign using a population-based computational model","volume":"17","author":"Alawieh","year":"2017","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0650","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12916-016-0666-7","article-title":"Erratum to: Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel [BMC Medicine 2016;14:95]","volume":"14","author":"Yaari","year":"2016","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0655","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-016-0637-z","article-title":"Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel","volume":"14","author":"Yaari","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2026.128707_bb0660","article-title":"Estimating the risk of re-emergence after stopping polio vaccination","volume":"3:178","author":"Sasaki","year":"2012","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0665","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tpb.2009.08.003","article-title":"Population dynamics of live-attenuated virus vaccines","volume":"77","author":"Wagner","year":"2010","journal-title":"Theor Popul Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0670","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11538-007-9255-4","article-title":"Circulating vaccine derived polio viruses and their impact on global polio eradication","volume":"70","author":"Wagner","year":"2008","journal-title":"Bull Math Biol"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128707_bb0675","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/23744235.2025.2503467","article-title":"The association of oral polio vaccine doses and severity of paralysis: An analysis of wild poliovirus type 1 cases in Pakistan","volume":"57","author":"Soghaier","year":"2025","journal-title":"Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128707_bb0680","doi-asserted-by":"crossref","first-page":"990042","DOI":"10.3389\/fpubh.2022.990042","article-title":"Cost-effectiveness of various immunization schedules with inactivated Sabin strain polio vaccine in Hangzhou, China","volume":"10","author":"Xu","year":"2022","journal-title":"Front Public Health"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128707_bb0685","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/vaccines9101062","article-title":"Cost-effectiveness of three poliovirus immunization schedules in Shanghai, China","volume":"9","author":"Ren","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128707_bb0690","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1542\/peds.2005-2358","article-title":"Decision analysis in planning for a polio outbreak in the United States","volume":"118","author":"Jenkins","year":"2006","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128707_bb0695","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1467-842X.2001.tb00648.x","article-title":"Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia","volume":"25","author":"Tucker","year":"2001","journal-title":"Aust N Z J Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128707_bb0700","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/wber\/lhq018","article-title":"Stop! The polio vaccination cessation game","volume":"24","author":"Barrett","year":"2010","journal-title":"World Bank Econ Rev"},{"key":"10.1016\/j.vaccine.2026.128707_bb0705","author":"World Health Assembly"},{"key":"10.1016\/j.vaccine.2026.128707_bb0710","author":"Global Polio Eradication Initiative"},{"issue":"Suppl 1(Suppl 1)","key":"10.1016\/j.vaccine.2026.128707_bb0715","doi-asserted-by":"crossref","first-page":"S424","DOI":"10.1093\/infdis\/jit843","article-title":"Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination","volume":"210","author":"Kisjes","year":"2014","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128707_bb0720","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1017\/S0950268810001676","article-title":"Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics","volume":"139","author":"Rahmandad","year":"2011","journal-title":"Epidemiol Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0725","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002599","article-title":"Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge","volume":"8","author":"Hird","year":"2012","journal-title":"PLoS Pathog"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2026.128707_bb0730","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1093\/cid\/ciy634","article-title":"Immune priming and long-term persistence of memory B cells after inactivated poliovirus vaccine in macaque models: support for at least 2 doses","volume":"67","author":"Bhaumik","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2026.128707_bb0735","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/ciy633","article-title":"Immunogenicity of new primary immunization schedules with inactivated poliovirus vaccine and bivalent oral polio vaccine for the polio endgame: a review","volume":"67","author":"Bandyopadhyay","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128707_bb0740","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1473-3099(15)00219-4","article-title":"Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study","volume":"15","author":"O\u2019Ryan","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"48","key":"10.1016\/j.vaccine.2026.128707_bb0745","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1016\/j.vaccine.2015.09.039","article-title":"Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial","volume":"33","author":"Anand","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128707_bb0750","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa1202541","article-title":"Priming after a fractional dose of inactivated poliovirus vaccine","volume":"368","author":"Resik","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128707_bb0755","doi-asserted-by":"crossref","first-page":"A113","DOI":"10.1016\/j.vaccine.2022.03.027","article-title":"Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks","volume":"41","author":"Estivariz","year":"2023","journal-title":"Vaccine"},{"issue":"99","key":"10.1016\/j.vaccine.2026.128707_bb0760","first-page":"719","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, September 2024: conclusions and recommendations","volume":"49","author":"World Health Organization","year":"2024","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.128707_bb0765","author":"World Health Organization"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128707_bb0770","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3390\/vaccines12121308","article-title":"Monitoring the risk of type-2 circulating vaccine-derived poliovirus emergence during roll-out of type-2 novel oral polio vaccine","volume":"12","author":"Peak","year":"2024","journal-title":"Vaccines"},{"issue":"50","key":"10.1016\/j.vaccine.2026.128707_bb0775","first-page":"613","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, October 2021: conclusions and recommendations","volume":"96","author":"World Health Organization","year":"2021","journal-title":"Wkly Epidemiol Rec"},{"issue":"40","key":"10.1016\/j.vaccine.2026.128707_bb0780","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1016\/j.vaccine.2021.08.065","article-title":"Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial","volume":"39","author":"Zaman","year":"2021","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128707_bb0785","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2017.03.008","article-title":"Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule","volume":"35","author":"Anand","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128707_bb0790","doi-asserted-by":"crossref","first-page":"100133","DOI":"10.1016\/j.lanwpc.2021.100133","article-title":"Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: an open-label, randomized, controlled trial","volume":"10","author":"Wang","year":"2021","journal-title":"Lancet Reg Health \u2013 Western Pacific"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128707_bb0795","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coviro.2013.05.007","article-title":"Poliovirus vaccination options for achieving eradication and securing the endgame","volume":"3","author":"Estivariz","year":"2013","journal-title":"Curr Opin Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128707_bb0800","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa1202541","article-title":"Priming after a fractional dose of inactivated poliovirus vaccine","volume":"368","author":"Resik","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128707_bb0805","author":"Gavi the Vaccine Alliance"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128707_bb0810","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-005032","article-title":"Assessing vaccine introduction and uptake timelines in Gavi-supported countries: are introduction timelines accelerating across vaccine delivery platforms?","volume":"6","author":"Luthra","year":"2021","journal-title":"BMJ Global Health"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128707_bb0815","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004952","article-title":"Estimating population immunity against serotype-two poliomyelitis from the inactivated polio vaccine in routine immunization across 112 countries: a modelling study","volume":"23","author":"Gray","year":"2026","journal-title":"PLoS Med"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128707_bb0820","first-page":"285","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, March 2024: conclusions and recommendations","volume":"99","author":"World Health Organization","year":"2024","journal-title":"Wkly Epidemiol Rec"},{"issue":"100","key":"10.1016\/j.vaccine.2026.128707_bb0825","first-page":"193","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, March 2025: conclusions and recommendations","volume":"23","author":"World Health Organization","year":"2025","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.128707_bb0830","author":"Global Polio Eradication Initiative"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128707_bb0835","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1473-3099(20)30555-7","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial","volume":"21","author":"Bandyopadhyay","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128707_bb0840","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S1473-3099(19)30301-9","article-title":"Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis","volume":"19","author":"Macklin","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128707_bb0845","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/14760584.2023.2161519","article-title":"A review of the DTaP-IPV-HB-PRP-T hexavalent vaccine in pediatric patients","volume":"22","author":"Dakin","year":"2023","journal-title":"Expert Rev Vaccines"},{"issue":"7968","key":"10.1016\/j.vaccine.2026.128707_bb0850","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41586-023-06212-3","article-title":"Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3","volume":"619","author":"Yeh","year":"2023","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128707_bb0855","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S1473-3099(25)00285-3","article-title":"Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial","volume":"25","author":"Mercer","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128707_bb0860","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/pathogens13030224","article-title":"Inactivated poliovirus vaccine: recent developments and the tortuous path to global acceptance","volume":"13","author":"Sutter","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2026.128707_bb0865","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/vaccines14030216","article-title":"Research progress towards poliovirus virus-like particle vaccines: a review","volume":"14(3)","author":"Han","year":"2026","journal-title":"Vaccines"},{"issue":"41","key":"10.1016\/j.vaccine.2026.128707_bb0870","doi-asserted-by":"crossref","first-page":"909","DOI":"10.15585\/mmwr.mm7341a1","article-title":"Update on vaccine-derived poliovirus outbreaks - worldwide, January 2023-June 2024","volume":"73","author":"Namageyo-Funa","year":"2024","journal-title":"Morb Mortal Wkly Rep (MMWR)"},{"key":"10.1016\/j.vaccine.2026.128707_bb0875","author":"Global Polio Eradication Initiative"},{"key":"10.1016\/j.vaccine.2026.128707_bb0880","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128707_bb0885","doi-asserted-by":"crossref","first-page":"A58","DOI":"10.1016\/j.vaccine.2022.02.022","article-title":"Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019\u20132021","volume":"41","author":"Snider","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128707_bb0890","author":"World Health Organization"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:40:59Z","timestamp":1785249659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":178,"alternative-id":["S0264410X26005165"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128707","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global cessation of bivalent oral polio vaccine (bOPV): A comprehensive review of modeling studies from 2000 to 2025","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128707"}}